The StrandOmics platform works toward a world where one can foresee and possibly mitigate the occurrence of diseases that are either inherited or are at a major risk of developing. By focusing on clinical interpretation and reporting of genomic data, we can scan an individual’s genomic information and determine the likelihood of a person developing certain diseases,” says Chandru.
The core architecture of Strand’s products is a proprietary platform called AVADISTM, an acronym for Access, Visualize, Analyze, DIScover. These products include GeneSpring—a product for integrated biological research, StrandNGSTM—a pipeline package for Next Generation Sequencing data analysis from raw DNA sequence data alignment to variant calling and biological interpretation, iManageTM—a tool for large-scale biological image management, and a Virtual Liver to enable in silico toxicity screening.
The company’s GrammaticaTM is a proprietary natural language processing engine honed for the last 8 years for text written in English.
Strand is focused on fundamentally changing the diagnostics and treatment landscape
Strand has organically grown in the computational biology and bioinformatics sector, with more than 200 multi disciplinary scientists working together with an appreciation for both laboratory processes and the software development life cycle.
The company’s clientele comprise of more than 2,000 academic and pharma labs, molecular diagnostics and pathology labs, community hospitals and oncology centers offering clinical genomics diagnostics which serve over 100,000 patients. The largest commercial adoption of genomics for tumor profiling in the world emerged from a unique case study conducted by Strand’s partnership with Health Care Global Enterprises in India. Using Strand’s clinical genomics solutions for oncology, which includes both cancer risk assessment from saliva DNA as well as molecular diagnosis, Strand and HCG together ran a pilot program on over 50 samples to demonstrate value to clinicians and patients. The results are very successful and HCG is in the process of making this profiling the standard of care for breast, ovarian, colorectal and lung cancers.
Strand’s NGS-based clinical diagnostics tests for cancer, cardiovascular and other diseases are driving the innovation to reduce costs and turnaround times by automating through the StrandOmics platform. “Strand is focused on fundamentally changing the diagnostics and treatment landscape. Our aim is to make genomic testing a part of routine medical care, thereby empowering clinicians to make more informed decisions and offering physicians, short and personalized patient reports,” concludes Dr. Chandru.